Singapore, February 1, 2026 — Axcynsis Therapeutics announced the commencement of its Phase 1 first-in-human clinical trial in the United States for AT03-65 (NCT06809114), a differentiated antibody-drug conjugate designed to target CLDN6-positive solid tumors. The initiation of the trial marks an important milestone in the clinical development of Axcynsis’s AxcynDOT™ platform and its broader ADC pipeline.
About the study
NCT06809114 is a first-in-human Phase 1 study evaluating the safety and pharmacology of AT03-65 in patients with advanced CLDN6-positive solid tumors. The trial includes dose escalation and dose expansion components, supporting the identification of an appropriate dose and early signals of clinical activity.
About Axcynsis Therapeutics
Axcynsis Therapeutics is a Singapore-headquartered biotechnology company focused on developing innovative antibody-drug conjugate therapies for cancer. The company is advancing a pipeline of differentiated oncology candidates designed to address significant unmet medical needs, and has recently commenced its Phase 1a clinical trial in the United States in Q1 2026.